The UK Intellectual Property Office has issue the UK patent covering the polymorph representing a preferred stable form of entinostat of Syndax Pharmaceuticals with “key .laims covering the polymorph form B and the manufacturing process by which it is derived”.
Syndax Pharmaceuticals filed the patent application as the Patent Cooperation Treaty (PCT) which will provide platform for additional worldwide filings in the following countries Japan, China, India, South Africa and Brazil. Syndax has filed patent application for entinostat in the Us, Europe, Argentina, Venezuela, Taiwain, Kuwait and Saudi Arabia.
Entinostat is an oral highly selective class I Histone deacetylase (HDAC) inhibitor. It has very long half life which will allow it to be dose once a week or once every other week. It’s currently being studied in phase II clinical trials listed below
- Add-on therapy to aromatase inhibitors in advanced breast cancer
- Add-on therapy to erlotinib in metastatic lung cancer
- Add-on therapy with azacitidine in non-small-cell lung cancer and advanced colorectal cancer (under CRADA w/ the NCI)
- Monotherapy in Hodgkin’s lymphoma.